Sanofi: Carcinoma, Non-Small-Cell Lung trials
The registry lists 47 Carcinoma, Non-Small-Cell Lung studies with Sanofi as lead sponsor. 1 are open to participants now and 17 have results posted.
Phase 1 12Phase 2 28Phase 3 8No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsRecruitingNCT07629960Phase 1/2
- Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEATerminatedNCT05245071Phase 2Results posted
- A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)TerminatedNCT04914897Phase 2Results posted
- Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLCTerminatedNCT04524689Phase 2Results posted
- Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)TerminatedNCT04394624Phase 2Results posted
- SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer PatientsTerminatedNCT04154956Phase 3Results posted
- A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced MalignanciesTerminatedNCT03829501Phase 1/2Results posted
- Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced MalignanciesTerminatedNCT03367819Phase 1/2Results posted
- Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal MetastasesCompletedNCT02616393Phase 2Results posted
- Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet ChemotherapyCompletedNCT00777179Phase 2Results posted
- Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus GemcitabineCompletedNCT00753714Phase 2Results posted
- Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC PatientsCompletedNCT00418886Phase 3Results posted
- ZD6474 (ZACTIMA™) Phase III Study in EGFR FailuresCompletedNCT00404924Phase 3Results posted
- Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung CancerTerminatedNCT00378573Phase 2Results posted
- Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior ChemotherapyCompletedNCT00364351Phase 3Results posted
- Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00356122Phase 2Results posted
- ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung CancerCompletedNCT00312377Phase 3Results posted
- Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung AdenocarcinomaCompletedNCT00284141Phase 2Results posted
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsTerminatedNCT05241873Phase 1
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLCTerminatedNCT05153408Phase 1
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCTerminatedNCT04862780Phase 1
- External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLCStatus unknownNCT04697446
- Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTCApproved for marketingNCT04204928
- KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line ChemotherapyTerminatedNCT01487174Phase 3
- Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung CancerCompletedNCT01263886Phase 2
- SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung CancerCompletedNCT01086254Phase 2
- Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung CancerCompletedNCT00819728Phase 2
- Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain MetastasesTerminatedNCT00807170Phase 1
- Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid TumorsCompletedNCT00777699Phase 1
- Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid TumorsCompletedNCT00756847Phase 1
- Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid TumorsCompletedNCT00692640Phase 1
- Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or ErlotinibCompletedNCT00522145Phase 2
- ZD6474(Vandetanib) + Alimta Combo StudyCompletedNCT00506051Phase 1
- Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLCCompletedNCT00496275Phase 1
- Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.CompletedNCT00425191Phase 2
- ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC)CompletedNCT00424853Phase 2
- Study of XL647 in Subjects With Non-Small-Cell Lung CancerCompletedNCT00364780Phase 2
- Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC PatientsTerminatedNCT00271323Phase 2
- Efficacy Study of GEMOX Combination and Vinorelbine in NSCL PatientsCompletedNCT00271271Phase 2
- Docetaxel in Non Small Cell Lung Cancer (NSCLC)TerminatedNCT00263016Phase 2
- ZD6474 Phase IIa Dose Finding Multicentre StudyCompletedNCT00252746Phase 2
- Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00087802Phase 3
- Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CarcinomaCompletedNCT00078455Phase 2
- ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT00071188Phase 2
- This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.CompletedNCT00059722Phase 2
- This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.CompletedNCT00047840Phase 2
- Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00017459Phase 3